NDA 021879 · Otsuka America Pharm
Nuedexta
Dextromethorphan Hydrobromide, Quinidine Sulfate · Oral
Priority reviewLast checked: Nov 19, 2026Latest source record: Jun 11, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 29, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
206
29 Phase 3, 17 recruiting
FAERS reports
3,631
1,230 serious, 282 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 22, 2026.
NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. NUEDEXTA is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of pseudobulbar affect (PBA). ( 1 )
Mechanism: Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. Quinidine increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 29, 2010 Original approval · Type 4 - New Combination · priority review LabelReviewSummary Review
1 products under this application
- NUEDEXTA · DEXTROMETHORPHAN HYDROBROMIDE 20MG; QUINIDINE SULFATE 10MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dextromethorphan Hydrobromide" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Evaluation of S (+) - Ketamine in AdultsPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04837170 · 12,000 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2022
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: Postoperative Pain; Adults; Anesthesia
- Safety and Efficacy Evaluation of S (+) - Ketamine in ChildrenPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04834427 · 3,000 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 1, 2024
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: S-ketamine; Esketamine; Acute Pain and 6 more
Sites: Beijing, China
- Combined Therapy of Methadone and DextromethrophanPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT01189097 · 1,500 participants (planned) · Start Apr 2008 · Primary completion Mar 2011
Drug: Dextromethorphan; Dextromethorphan · For: Opioid Abuse
Sites: Tainan, Taiwan
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypePivotal-lookingTerminated
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT02446132 · 1,197 participants · Start Nov 13, 2015 · Primary completion Sep 6, 2024
Drug: AVP-786 · For: Agitation in Patients With Dementia of the Alzheimer's Type
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 227 sites in all
- Open-Label Safety Study of AXS-05 in Subjects With DepressionPivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT04039022 · 876 participants · Start Jul 8, 2019 · Primary completion Oct 23, 2020
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets · For: Major Depressive Disorder; Treatment Resistant Depression; Depression
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bellflower, California · 51 sites in all
- Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07766655 · 705 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 2027
Drug: AXS-05 (dextromethorphan-bupropion); Bupropion and 1 more · For: Smoking Cessation
Sites: Phoenix, Arizona; Little Rock, Arkansas; Lemon Grove, California · 28 sites in all
- Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.Pivotal-lookingCompleted
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT03738917 · 668 participants · Start Feb 1, 2019 · Primary completion Nov 30, 2021
Drug: Dextromethorphan 15 milligrams; Ipratropium Bromide 20Micrograms Inhaler · For: Acute Bronchitis
Sites: Badalona, Spain; Balaguer, Spain; Barcelona, Spain · 12 sites in all
- Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)Pivotal-lookingCompleted
Avanir PharmaceuticalsIndustry
NCT00056524 · 600 participants (planned) · Start Feb 2003 · Primary completion Jun 2007
Drug: AVP-923 · For: Alzheimer's Disease; Stroke; Parkinson's Disease and 1 more
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 39 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall208
- off label use208
- product use in unapproved indication195
- death192
- drug ineffective192
- dizziness169
- therapy interrupted161
- fatigue145
- diarrhoea135
- nausea111
- somnolence104
- dysphagia102
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 16 |
| 2012 | 33 |
| 2013 | 38 |
| 2014 | 73 |
| 2015 | 559 |
| 2016 | 518 |
| 2017 | 414 |
| 2018 | 368 |
| 2019 | 331 |
| 2020 | 244 |
| 2021 | 190 |
| 2022 | 122 |
| 2023 | 212 |
| 2024 | 264 |
| 2025 | 201 |
| 2026 | 48 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nuedexta (Dextromethorphan HBr/Quinidine)
2024 spending
$173M
Beneficiaries
15,788
158,337 claims
Per beneficiary
$10,955
$26.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $212,633,559 |
| 2021 | $187,531,133 |
| 2022 | $183,244,625 |
| 2023 | $180,648,015 |
| 2024 | $172,956,424 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects.
Aylward M, Maddock J, Davies DE, et al. · Eur J Respir Dis 1984 · Clinical Trial, Comparative Study
- Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T, Schlenk R, Pfaff G, et al. · Arzneimittelforschung 1995 · Clinical Trial
- Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J, Rohrbacher M, Schmidt H, et al. · Pain 2009 · Clinical Trial
- Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers.
Demirbas S, Reyderman L, Stavchansky S · Biopharm Drug Dispos 1998 · Clinical Trial, Controlled Clinical Trial
- Design and evaluation of taste masked dextromethorphan hydrobromide oral disintegrating tablets.
Malladi M, Jukanti R, Nair R, et al. · Acta Pharm 2010 · Clinical Trial
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.